Search - tctmd.com

Displaying 61 - 80 of 605

Sort: Relevancy | Date

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for May 2024

Shelley Wood

May 31, 2024

News Daily News

AHA/ACC and Others Issue PAD Guideline Update With Focus on Collaborative Care

L.A. McKeown

May 17, 2024

Presentation EuroPCR 2024

Impact of valve type and anaesthesia strategy for TAVI – 5-year results of the SOLVE-TAVI trial

Presenter: Hans-Josef Feistritzer

May 14, 2024

News Daily News

TAVI Outcomes Linked to LV Recovery in Patients With Severe Dysfunction

Michael O'Riordan

May 06, 2024

News Conference News SCAI 2024

AI Picks Up on Info Operators Miss on Angiograms: AI-ENCODE

L.A. McKeown

May 03, 2024

News Conference News SCAI 2024

CALORI: More Support for Eschewing Fasting Protocols Preprocedure

L.A. McKeown

May 02, 2024

News Opinion CV Team Dispatch

May 2024 Dispatch for the CV Team

L.A. McKeown

May 01, 2024

News Daily News

FDA Approves Bioresorbable Scaffold for BTK Lesions

Michael O'Riordan

April 29, 2024

News Conference News ACC 2024

PREVENT Supports Early PCI for Vulnerable Plaque, With Reductions in MACE

L.A. McKeown

April 08, 2024

$Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC$

News Conference News ACC 2024

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Michael O'Riordan

April 08, 2024

$Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)$

Presentation ACC 2024

Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)

Presenter: Rasha K. Al-Lamee

April 08, 2024

Presentation ACC 2024

PREVENT: Preventive PCI versus Medical Therapy Alone for Treatment of Vulnerable Atherosclerotic Coronary Plaques

Presenter: Seung-Jung Park

April 07, 2024

News Opinion CV Team Dispatch

April 2024 Dispatch for the CV Team

L.A. McKeown

April 01, 2024

News Conference News CRT 2024

SAFE-MCS: Monitoring System Intercepts Bleeding in High-risk PCI

L.A. McKeown

March 15, 2024

News Conference News CRT 2024

Mixed Bag With DCBs for In-Stent Restenosis, Small Coronary Arteries

L.A. McKeown

March 14, 2024

News Daily News

Physicians (Mostly) Negative on Private Equity in Healthcare

Michael O'Riordan

March 13, 2024

News Daily News

DISCHARGE Data Reassure on Use of CCTA in Older Chest-Pain Patients

Michael O'Riordan

March 04, 2024

News Opinion CV Team Dispatch

March 2024 Dispatch for the CV Team

L.A. McKeown

March 01, 2024

News Daily News

Agent Coronary DCB Gets FDA Approval for In-Stent Restenosis

L.A. McKeown

March 01, 2024

News Daily News

Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

Michael O'Riordan

February 23, 2024

Advertisement

TCTMD’s Top 10 Most Popular Stories for May 2024

AHA/ACC and Others Issue PAD Guideline Update With Focus on Collaborative Care

Impact of valve type and anaesthesia strategy for TAVI – 5-year results of the SOLVE-TAVI trial

TAVI Outcomes Linked to LV Recovery in Patients With Severe Dysfunction

AI Picks Up on Info Operators Miss on Angiograms: AI-ENCODE

CALORI: More Support for Eschewing Fasting Protocols Preprocedure

May 2024 Dispatch for the CV Team

FDA Approves Bioresorbable Scaffold for BTK Lesions

PREVENT Supports Early PCI for Vulnerable Plaque, With Reductions in MACE

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)

PREVENT: Preventive PCI versus Medical Therapy Alone for Treatment of Vulnerable Atherosclerotic Coronary Plaques

April 2024 Dispatch for the CV Team

SAFE-MCS: Monitoring System Intercepts Bleeding in High-risk PCI

Mixed Bag With DCBs for In-Stent Restenosis, Small Coronary Arteries

Physicians (Mostly) Negative on Private Equity in Healthcare

DISCHARGE Data Reassure on Use of CCTA in Older Chest-Pain Patients

March 2024 Dispatch for the CV Team

Agent Coronary DCB Gets FDA Approval for In-Stent Restenosis

Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content